Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  2000-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/JCEM.85.9.6772PMID 10999782
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism.

  2000cited by this paper
• Different effects of IGF-I on insulin-stimulated glucose uptake in adipose tissue and skeletal muscle.

  2000cited by this paper
• Pharmacokinetics of insulin-like growth factor I in hypopituitarism: correlation with binding proteins.

  1999cited by this paper
• Growth hormone therapy in adults and children.

  1999cited by this paper
• Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency.

  1998cited by this paper
• Bone Mineral, Histomorphometry, and Body Composition in Adults with Growth Hormone Receptor Deficiency

  1998cited by this paper
• Normal intelligence with severe insulin-like growth factor I deficiency due to growth hormone receptor deficiency: a controlled study in a genetically homogeneous population.

  1998cited by this paper
• Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors.

  1997cited by this paper
• Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.

  1997cited by this paper
• Phenotype: genotype relationships in growth hormone insensitivity syndrome.

  1997cited by this paper
• Metabolic effects of recombinant human insulin-like growth factor-I in humans: comparison with recombinant human growth hormone

  1996cited by this paper
• Prismatic cases: Laron syndrome (primary growth hormone resistance) from patient to laboratory to patient.

  1995cited by this paper
• Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect.

  1995influential reference
• Combined recombinant human growth hormone and recombinant human insulin-like growth factor I: lack of synergy on whole body protein anabolism in normally fed subjects.

  1995cited by this paper
• Growth hormone (GH) insensitivity due to primary GH receptor deficiency.

  1994cited by this paper
• Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.

  1994cited by this paper
• IGF-I treatment of adult patients with Laron syndrome: preliminary results.

  1994cited by this paper
• IGF‐I treatment of adult patients with Laron syndrome: preliminary results

  1994cited by this paper
• Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans.

  1993cited by this paper
• A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.

  1993cited by this paper
• Pharmacokinetics of recombinant human insulin‐like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency

  1993cited by this paper
• Diverse growth hormone receptor gene mutations in Laron syndrome.

  1993cited by this paper
• Heated dorsal hand vein sampling for metabolic studies: a reappraisal.

  1992cited by this paper
• Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type)

  1992cited by this paper
• Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man.

  1992cited by this paper
• Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome

  1992cited by this paper
• Laron dwarfism and mutations of the growth hormone-receptor gene.

  1989cited by this paper
• Plasma reciprocal pool specific activity predicts that of intracellular free leucine for protein synthesis.

  1989cited by this paper
• The theoretical bases of indirect calorimetry: a review.

  1988cited by this paper
• Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults.

  1987cited by this paper
• Specific binding of human growth hormone but not insulin‐like growth factors by human adipocytes

  1986cited by this paper
• Use of reciprocal pool specific activities to model leucine metabolism in humans.

  1985cited by this paper
• Insulin-mediated reduction of whole body protein breakdown. Dose-response effects on leucine metabolism in postabsorptive men.

  1985cited by this paper
• Use of t-butyldimethylsilylation in the gas chromatographic/mass spectrometric analysis of physiologic compounds found in plasma using electron-impact ionization.

  1984cited by this paper
• Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: further evidence for the action of insulin-like growth factors through the insulin receptor.

  1981cited by this paper
• A microprocessor controlled mass spectrometer for the fully automated purification and isotopic analysis of breath carbon dioxide.

  1979cited by this paper
• Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 Years

  1974cited by this paper
• Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Testosterone Deficiency in Young Men: Marked Alterations in Whole Body Protein Kinetics, Strength, and Adiposity*

  year unknowncited by this paper

• New insights on the cardiovascular effects of IGF-1

  2023cites this paper
• Causal associations between insulin-like growth factor 1 and vitamin D levels: a two-sample bidirectional Mendelian randomization study

  2023cites this paper
• Unexpected role for IGF-1 in starvation: Maintenance of blood glucose

  2022cites this paper
• Investigation of the Interplay between Circulating Lipids and IGF-I and Relevance to Breast Cancer Risk: An Observational and Mendelian Randomization Study

  2021cites this paper
• Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador

  2020cites this paper
• A rationale for the treatment of short stature in children with the combination of recombinant human growth hormone (rhGH) and recombinant human insulin-like growth factor-I (rhIGF-I).

  2020cites this paper
• The Interrelationship between Insulin-Like Growth Factor 1, Apolipoprotein E ε4, Lifestyle Factors, and the Aging Body and Brain

  2020cites this paper
• The effects of recombinant human insulin‐like growth factor‐1/insulin‐like growth factor binding protein‐3 administration on lipid and carbohydrate metabolism in recreational athletes

  2020cites this paper
• Estimating the effect of lipids on IGF axis and subsequent breast cancer risk

  2020cites this paper
• A novel homozygous point mutation and deletion in exon 3 of growth hormone receptor causes laron syndrome: A case study

  2019cites this paper
• ALTERATIONS IN THYROID HORMONE LEVELS FOLLOWING GROWTH HORMONE REPLACEMENT EXERT COMPLEX BIOLOGICAL EFFECTS.

  2018cites this paper
• Insulin-like growth factors: actions on the skeleton.

  2018cites this paper
• Metabolomics changes in patients with PAPP-A2 deficiency in response to rhIGF1 treatment.

  2018cites this paper
• Analyse par spectrométrie de masse des tubulines et de l'hormone de croissance

  2018cites this paper
• Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome and Lipodystrophy: Pathophysiology and Current Therapeutic Interventions

  2017cites this paper
• A Functional Interplay between IGF-1 and Adiponectin

  2017cites this paper
• Insulin-like growth factor-1 deficiency and metabolic syndrome

  2016cites this paper
• Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy

  2016cites this paper
• Doping in sport: effects, harm and misconceptions

  2015cites this paper
• The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration on Body Composition and Physical Fitness in Recreational Athletes.

  2015cites this paper
• Metabolic Effects of Growth Hormones in Children

  2015cites this paper
• Optimizing IGF-I for skeletal muscle therapeutics.

  2014cites this paper
• The Insulin-Like Growth Factors in Adipogenesis and Obesity

  2014cites this paper
• Effects of Exogenous Growth Hormone on Growth Hormone-Insulin-Like Growth Factor Axis of Human Gastric Cancer Cell

  2014cites this paper
• The Contribution of Reg Family Proteins to Cell Growth and Survival in Pancreatic Islets

  2014cites this paper
• Emerging treatment options for patients with Laron syndrome

  2014cites this paper
• Cushing, acromegaly, GH deficiency and tendons.

  2014cites this paper
• Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection

  2013cites this paper
• Insulin-like growth factor -I deficiency, insulin sensitivity, and glucose metabolism

  2013cites this paper
• Serum IGF‐1 Is Insufficient to Restore Skeletal Size in the Total Absence of the Growth Hormone Receptor

  2013cites this paper
• The detection of growth hormone and insulin-like growth factor-I misuse in athletes

  2013influential citation
• Neuroendocrine dysregulation and the growth hormone–IGF-1 axis in anorexia nervosa

  2012cites this paper
• GH/IGF‐I axis and matrix adaptation of the musculotendinous tissue to exercise in humans

  2012cites this paper
• The insulin-like growth factors in adipogenesis and obesity.

  2012cites this paper
• Serum IGF1 and insulin levels in girls with normal and precocious puberty.

  2012cites this paper
• Mecasermin

  2012cites this paper
• Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.

  2012cites this paper
• IN VITRO IN VIVO METHODS AND PHARMACOKINETIC MODELS FOR SUBCUTANEOUSLY ADMINISTERED PEPTIDE DRUG PRODUCTS

  2012cites this paper
• Metabolic Actions of Growth Hormone

  2011influential citation
• Insulin-Like Growth Factor-I and Insulin-Like Growth Factor Binding Protein-3 Cotreatment versus Insulin-Like Growth Factor-I Alone in Two Brothers with Growth Hormone Insensitivity Syndrome: Effects on Insulin Sensitivity, Body Composition and Linear Growth

  2011cites this paper
• Pathogenesis and treatment of HIV lipohypertrophy

  2011cites this paper
• Common Variations in Endocrine Genes in Relation to Growth and Body Composition: Studies in childhood and adolescence

  2011cites this paper
• Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance.

  2010cites this paper
• Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study.

  2010cites this paper
• 胰岛素生长因子-1受体信号通路与肺癌的研究进展

  2010cites this paper
• Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample.

  2009cites this paper
• Can Growth Hormone Counteract the Catabolic Effects of Steroids?

  2009cites this paper
• IGF-I abuse in sport.

  2009cites this paper
• IGF-I abuse in sport: current knowledge and future prospects for detection.

  2009cites this paper
• Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials

  2008cites this paper
• IGF-I improved bone mineral density and body composition of weaver mutant mice.

  2008cites this paper
• Izomero, izomtömeg növelése hormonokkal és egyéb szerekkel, edzésscl társítva

  2007cites this paper
• Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.

  2007cites this paper
• Improvement of muscle mass and force by certain hormones and endogen factors, contributing in muscle development

  2007cites this paper
• Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with turner syndrome.

  2007cites this paper
• Defining the role of IGF-I therapy for short children.

  2007cites this paper
• Association between an IGF-I gene polymorphism and body fatness: differences between generations.

  2006cites this paper
• Concentraciones de estradiol y acetato de noretisterona y mediciones antropométricas en menopáusicas obesas y no obesas

  2006cites this paper
• High growth hormone levels in clinically short stature children.

  2006cites this paper
• Beneficios nutricionales de la hormona del crecimiento y de la testosterona en el niño y adolescente

  2006cites this paper
• Short‐term suppression of elevated growth hormone concentrations following insulin‐like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates

  2006cites this paper
• Pharmacodynamic Considerations with Recombinant Human Insulin-Like Growth Factor-I in Children

  2005cites this paper
• Are the metabolic effects of GH and IGF-I separable?

  2005cites this paper
• Insulin-like growth factor binding protein-3 mediates cytokine-induced mesangial cell apoptosis.

  2005cites this paper
• Umbilical serum insulin-like growth factor 1 (IGF-1) in newborns: effects of gestational age, postnatal age, and nutrition.

  2003cites this paper
• Five weeks of insulin-like growth factor-I treatment does not alter glucose kinetics or insulin sensitivity during a hyperglycemic clamp in older women.

  2003cites this paper
• Apparent Induction of Partial Thymic Regeneration in a Normal Human Subject: A Case Report

  2003cites this paper
• Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

  2002cites this paper
• Growth Hormone Therapy and its Relationship to Insulin Resistance, Glucose Intolerance and Diabetes Mellitus

  2002cites this paper
• The effect of milk consumption immediately following resistance exercise on protein degradation in untrained males before and after a 10-week resistance training protocol

  2002cites this paper
• Update in growth hormone insensitivity syndrome

  2002cites this paper
• One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women.

  2001cites this paper
• Recombinant human growth hormone and recombinant human insulin-like growth factor I diminish the catabolic effects of hypogonadism in man: metabolic and molecular effects.

  2001cites this paper
• Send Orders of Reprints at Reprints@benthamscience.org Rodent Models to Study the Roles of the Gh–igf-1 Axis in the Aging and Anti-aging Effects of Calorie Restriction

  year unknowncites this paper